Canada Pharmaceuticals and Healthcare Report Q3 2009

Publication Date	June 2009
Publisher	Business Monitor
Product Type	Report
Pages	73
ISBN Number	not applicable
Product Code	BMI02091

Buy this product or for assistance call +44 20 7060 7474

PDF £250.00$416 | €280

FAX Order above formats by FAX

Summary

For BMI's Pharmaceutical and Healthcare Q309 Report for Canada, we believe the total drug market value will increase from US$22.4bn in 2008 to US$37.2bn by 2013, representing a compound annual growth rate (CAGR) of 10.7% in US dollar terms. We believe that the generic and patented drug markets will reach proportions by value of 26% and 62% of the total drug market sector, respectively, by 2013.

We believe that the main drivers for growth include the 16% increase in the health burden that noncommunicable diseases will present for the country through to 2030.

Canada is the only country on the North and Central American continent to appear on the United States Trade Representative (USTR) Special 301 Priority Watch List in 2009, despite the IP shortcomings of the developed nations including Mexico and Guatemala. Its inclusion appears to have arisen from ongoing delays in reforming copyright laws, particularly with regard to counterfeit product entry and circulation within the country. The earlier submission from the Trade Association of the Pharmaceutical Manufacturers of America (PhRMA) outlined that data exclusivity was not universally enforced for drugs that are not marketed in Canada, despite the implementation of the 2006 legislation amendment to this effect.

The main concerns indicated by PhRMA relate to the regulation and protection of patented drugs and the premature entry of generic medicines into the healthcare market. Innovative pharmaceutical firms will be discouraged from investing in the Canadian drug market while such biases remain and we would urge the government to reform its medicine regulatory policy in order to remove the country from the priority watch list. BMI cautions that Canada's inclusion on this list will deal a blow to the pharmaceutical and biotech industry within the country, particularly since the state is trying to encourage investment into this sector.

In BMI's Business Environment Rankings for Q309, Canada is once again placed third out of the 10 Americas markets surveyed, having been overtaken by Puerto Rico in Q408. The new rating criteria serve to reinforce our estimation of the country's potential owing to a stronger emphasis on the regulatory environment, which we see as a major factor affecting the business environment for drugmakers.

Content

Executive Summary
SWOT Analysis
Canada Pharmaceuticals And Healthcare Industry SWOT
Canada Political SWOT
Canada Economic SWOT
Pharmaceutical Business Environment Ratings
Regional Pharma Business Environment Ratings
Limits of Potential Returns
Risks to Realisation Of Returns
Canada - Market Summary
Regulatory Regime
Intellectual Property Regime Developments
Pricing Regime and Reimbursement Issues
Reimbursement Regime
Recent Pricing and Reimbursement Developments
Industry Developments
Epidemiology
Healthcare Sector
Health Expenditure
- Table: Sustainability Of Public Health Expenditure And Pharmaceutical Approval Indicators
National Pharmaceuticals Strategy
Pharmaceutical Industry
Recent Company Activity
Pharmaceutical Re-import Policy
Research and Development Sector
Biotechnology
Medical Devices Industry
Recent Developments in The Medical Devices Industry
Industry Forecast Scenario
Overall Market Forecast
- Table: Canada - Drug Market Indicators
Key Growth Factors - Industry
- Table: Canada - Health Expenditure Indicators, Historical Data And Forecasts
Key Growth Factors - Macroeconomic
Can The Canadian Economy 'Decouple'?
- Table: Canada - Economic Activity
Prescription Market Forecast
- Table: Canada - Prescription Market Indicators, Historical Data And Forecasts (US$mn unless otherwise stated)
Patented Market Forecast
- Table: Canada - Patented Market Indicators, Historical Data and Forecasts
Generics Market Forecast
- Table: Canada - Generics Market Indicators, Historical Data and Forecasts
OTC Market Forecast
- Table: Canada - OTC Market Indicators, Historical Data And Forecasts (US$mn unless otherwise stated)
Pharmaceutical Export/Import Forecasts
- Table: Canada - Pharmaceutical Trade Indicators, Historical Data and Forecasts (US$mn)
Medical Devices Forecast
- Table: Canada - Medical Device Market Forecast, Historical Data And Forecasts
Other Healthcare Data
- Table: Canada - Other Health And Healthcare Indicators, Historical Data And Forecasts
Competitive Landscape
- Table: Canada's Leading Generics Firms, 2006
Company Profiles
Leading Multinational Manufacturers
Pfizer
GlaxoSmithKline
Novartis
Indigenous Manufacturers
Apotex
Country Snapshot: Canada Demographic Data
Section 1: Population
- Table: Demographic Indicators, 2005-2030
- Table: Rural/Urban Breakdown, 2005-2030
Section 2: Education And Healthcare
- Table: Education, 2000-2003
- Table: Vital Statistics, 2005-2030
Section 3: Labour Market And Spending Power
- Table: Employment Indicators, 2001-2006
- Table: Consumer Expenditure, 2000-2012 (US$)
- Table: Average Annual Manufacturing Wages, 2000-2012
BMI Forecast Modelling
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
- Table: Pharmaceutical Business Environment Indicators
Weighting
- Table: Weighting Of Components
Sources